XML 29 R22.htm IDEA: XBRL DOCUMENT
v3.25.3

Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | # 13. Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders The following table sets forth the computation of basic and diluted net income (loss) per share attributable to our common shareholders for the three and nine months ended September 30, 2025 and 2024, respectively (in thousands, except share and per share amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Net income (loss) attributable to Adaptive Biotechnologies Corporation |  | $ | 9,546 |  |  | $ | (32,071 | ) |  | $ | (45,920 | ) |  | $ | (125,800 | )
Weighted-average shares outstanding - basic |  |  | 152,432,307 |  |  |  | 147,516,398 |  |  |  | 151,248,398 |  |  |  | 146,908,234 |
Incremental shares attributable to share-based compensation plans |  |  | 10,729,800 |  |  |  | — |  |  |  | — |  |  |  | — |
Weighted-average shares outstanding - diluted |  |  | 163,162,107 |  |  |  | 147,516,398 |  |  |  | 151,248,398 |  |  |  | 146,908,234 |
Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  | $ | 0.06 |  |  | $ | (0.22 | ) |  | $ | (0.30 | ) |  | $ | (0.86 | )
The number of weighted-average common stock equivalents excluded from the calculation of diluted net income (loss) per share attributable to our common shareholders because of their anti-dilutive effect were 5.9 million and 26.9 million for the three months ended September 30, 2025 and 2024, respectively, and 28.0 million and 27.0 million for the nine months ended September 30, 2025 and 2024, respectively. These common stock equivalents are comprised of shares that may be issued under our stock option, restricted stock, market-based restricted stock and performance-based restricted stock programs.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration